Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
PREvention CAncer through physical FITness (PreCaFit)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain,United States
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-09-01
End date: 2025-08-31
Duration (months): 36.0
Total project cost (EUR): 245732.16
EU funding (EUR): 245732.16
Participants: 2
Project status: SIGNED

Cancer is the second leading cause of death worldwide, accounting for 18.1 million new cases and 9.6 million deaths in 2018, and representing the highest economic burden to modern health care systems with ~$1.16 trillion per year. Exploration of gender or race disparity in cancer susceptibility has not been common practice. Together with cancer, cardiometabolic disease are the largest contributors to the burden of chronic disease worldwide. Every year many cases of cancer seem attributable to metabolic disease. Growing evidence has firmly established that both low fitness and physical inactivity are strongly associated with many chronic conditions and all-cause mortality. Therefore, there is an urgent need to unravel whether fitness and physical activity are related to cancer. The PreCaFit project will fill the gaps in the knowledge examining the relationship between fitness, physical activity and cancer. Further, to ensure the scalability of the results, we will examine the effects of exercise on cancer biomarkers. This will produce a large impact in science and society since it will provide the first step toward feasible, effective and safe prevention strategies. The use of objective measurements and a unique set of techniques for data acquisition, the epidemiological collection in a large sample, the lab research at Stanford University (Prof. Myers), the secondments in Europe at Prof. Ekelund lab for learning data pooling and harmonization techniques, and at Prof. Riboli lab for learning about cancer epidemiology and biomarkers, and the pilot randomized controlled trial on exercise and cancer biomarkers at UGR (Prof. Ortega) place this project in pole position to address how lifestyle behaviours might mitigate cancer. To do so, the training, management skills, dissemination/exploitation and communication/outreach activities in the top-level hosts and secondment institutions ensure the scientific excellence and determination with improved career possibilities.

Keywords: physical activity,physical fitness,adults,randomized controlled trial,non communicable diseases,reference standards,race,cardiometabolic disease
CONtexts of extremism iN mEna and balKan socieTies (CONNEKT)

Framework: Horizon 2020 — Societal Challenges
Programme: Europe in a changing world - inclusive, innovative and reflective societies
Theme: Reflective societies - cultural heritage and European identity
Action type: Research and Innovation actions
Countries involved: Austria,Spain,Egypt,Spain,North Macedonia,Tunisia,Bosnia and Herzegovina,Belgium,Bulgaria,Jordan,France,Morocco,Kosovo
Call: Drivers and contexts of violent extremism in the broader MENA region and the Balkans (H2020-SC6-GOVERNANCE-2019, 2019)
Start date: 2020-02-01
End date: 2024-01-31
Duration (months): 48.0
Total project cost (EUR): 2933802.5
EU funding (EUR): 2933802.5
Participants: 14
Project status: SIGNED

CONNEKT is a research and action project involving 14 partners from the EU, MENA and Balkans and targeting 8 countries in the MENA and Balkans region (Egypt, Jordan, Tunisia, Morocco, Bosnia and Herzegovina, Kosovo, North Macedonia and Bulgaria) that will run for 3.5 years. Its purpose is to establish a multi-dimensional map of drivers of violent extremism (VE) among youth aged 12-30 in MENA and Balkans and to identify the interplay between them. The multi-disciplinary research and the multi-stakeholder approach will allow the enrichment of empirical and academic research in order to draw a comprehensive picture of VE drivers among youth in target countries. Using a building-blocks methodology the project will be staged to allow the findings from one phase to inform research and data analysis for the following phases at key milestones. A final stage will be devoted to research on prevention of VE from a community perspective and will converge in a set of actions and recommendations on prevention measures implemented at a local and community level. Objective 1: Mapping past and current country strategies and approaches towards radicalisation and VE in Europe, MENA and Balkans. Objective 2: Drawing a comprehensive picture of radicalisation drivers among youth in Egypt, Jordan, Tunisia, Morocco, Bosnia and Herzegovina, Kosovo, North Macedonia and Bulgaria. Objective 3: Establishing a cartography of conducive collective contexts of radicalisation and VE in MENA and Balkans involving diverse stakeholders Objective 4: Identifying measures, strategies and policies at state, community, local and society level to prevent radicalisation and VE in target countries Objective 5: Implementing pilot experiences of context intervention in target countries in liaison with local authorities and civil society actors Objective 6: Transferring results and recommendations to multi-level policy-makers in target countries and to the EU.

Keywords: violent extremism,youth,women,civil society,prevention,security,mena,balkans
THE ONLY WALKING REHABILITATION DEVICE THAT FITS THE CAPABILITIES OF THE FRAIL ELDERLY & NEUROLOGICAL IMPAIRED (Balanseat Phase-1)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Israel
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2018-12-01
End date: 2019-05-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

One of the common gait impairments among the elderly is reduction in trunk and pelvic rotation, which leads to increased risk of falls and loss of independence. However, common rehabilitation devices focus mainly on leg exercise and ignore the effect of trunk and pelvic rotation on walking. Moreover, the frail senior, as well as the neurologically impaired patient who suffer from advanced gait impairments lack the strength to cope with leg exercises that are performed while walking. Therefore, this population deteriorates, becomes home-bound and falls. Mopair's device, Balanseat, applies thoraco-pelvic rotation and thighs extension to a seated user. Thus, the frail senior, as well as the neurologically impaired is expected to find this treatment the only training modality they can cope with. Moreover, Balanseat approach is assumed to provide the comprehensive treatment that exceeds beyond the existing leg-exercise approach. A case series with 19 frail residents from an assisted living home demonstrated marked improvement in the functional-parameters that are correlated to fall-risk and level of ambulation. Clinical indications from neurologically impaired patients, as well as from two home-users who use Balanseat for more than 6 months, are similar. In parallel to the commercialization of this fundamental device, Mopair is planning to pursue a sensor-embedded device that senses the user's capabilities and progression. Sensors' outcomes, that enable personalization of treatment programs, will lead Mopair to fulfil its long-term vision of developing an autonomous therapist for the frail elderly and neurologically impaired – maybe, the only modality that can survive the challenge of the growing of Balanseat target population together with the shrinking of the healthcare resources. Balanseat is a revolutionary solution for walking rehabilitation, reducing risk of falls and improving ambulation for older adults and neurological impaired.

Keywords: walking rehabilitation,elderly,therapy,walking skills,risk of falls
Disruptive high-performance polymers (i-CARE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: France
Call: SME instrument (H2020-EIC-SMEInst-2018-2020-3, 2019)
Start date: 2020-04-01
End date: 2022-09-30
Duration (months): 30.0
Total project cost (EUR): 3480375.0
EU funding (EUR): 2436262.5
Participants: 1
Project status: SIGNED

Energy Majors are looking for new polymeric materials that provide exceptional performance in use (e.g. mechanical properties, durability, easy processing) in extreme environments conditions (offshore equipment, hydrogen storage tanks, etc). Yet, their options are limited as all existing materials have their limitations. Also, sustainability and carbon footprint are increasingly important for them. DEMETA is an innovative French SME created in 2011 with the ambition to become a global leader in high-performance polymers synthesized through green chemistry. DEMETA will enter the Energy market with project i-CARE. i-CARE’s disruptive high-performance polymer is branded NexTene™. It relies on a patented, green chemistry compliant catalyst, polymerizing a waste product from the petroleum industry (DCPD). NexTene™ outperforms existing materials in extreme environments and has a 47% lower carbon footprint than epoxy and other conventional materials. NexTene™ will enable equipment for offshore equipment (windmill structures, pipelines coating, custom coating, buoyancy modules, etc.). To ensure rapid deployment, DEMETA has chosen a fabless business model, outsourcing in Europe its whole production (catalyst production and blending operations). DEMETA has already started establishing partnerships with Energy Majors and key stakeholders of the energy ecosystem in Europe and abroad. 27 letters of intents from potential clients and stakeholders have been gathered. Thanks to the Accelerator EIC i-CARE project, DEMETA will accelerate the remaining development and qualification tests to reach TRL 8 on NexTene™ applications. Thanks to the EC investors, we will start market deployment and reach TRL9 before 2022. I-CARE will contribute to Europe worldwide leadership in the high-performance polymers market.

Keywords: polymer,green chemistry,extreme environment,hydrogen storage tanks,performance composites,offshore equipment
Libralato rotary engine; a game-change for cost competitive gasoline engines and plug-in hybrid cars. (Libralato)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: SME instrument
Countries involved: United Kingdom,United Kingdom
Call: Small business innovation research for Transport (H2020-SMEINST-1-2014, 2014)
Start date: 2015-05-01
End date: 2015-10-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 2
Project status: CLOSED

The Libralato engine is the world’s first “one stroke” rotary Atkinson cycle engine, completing all of the engine phases in parallel in each rotation. It has a completely new thermodynamic cycle which is predicted to achieve around 40% efficiency using gasoline. This is achieved because of its asymmetrical expansion and compression volumes and because it does not need to convert the reciprocating motion of pistons into the rotational motion of the output shaft. The Libralato engine has only four principal moving parts: two rotors fixed by their own bearing, connected by a sliding vane and a rotating exhaust. It has no need for conventional cylinders, pistons, con-rods, crankshafts, valve trains and cam shafts. The engine is tuned for lean burn combustion, with high and constant levels of torque, very low vibration and very low exhaust temperature and noise reducing fuel consumption by two thirds and CO2 emissions by 50%. The proposed innovation project intends to; demonstrate and validate the performance of the engine in an operational environment; run a fully operation commercial pilot with fleet test; industrialisation of Libralato engine for high volume production; scaling of production capability for up to 20k units.

Keywords: innovative gasoline engine,one stroke engine,increased engine efficiency,reduced fuel consumption,reduced co2 emissions
Enhancing innovation management capacities of SMEs in Montenegro (MontEENegro)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Specific Grant agreement
Countries involved: Montenegro
Call: H2020 2D CONSULTATION EEN (H2020-EEN-SGA2-2017-2018, 2016)
Start date: 2017-01-01
End date: 2018-12-31
Duration (months): 24.0
Total project cost (EUR): 13400.0
EU funding (EUR): 13400.0
Participants: 4
Project status: CLOSED

Enterprise Europe Network is a main support instrument for innovation in SMEs. It will provide innovation support services as well as information and advisory services such as mentoring, coaching and partner search activities for SMEs wishing to develop cross-border innovation projects. Innovation support, as a service that EEN Montenegro will deliver, will be offered through two packages - Key Account Management (KAM) to support the innovation capacity of successful “SME instrument” applicants benefiting from Horizon 2020 specific supporting mechanism, and Services to enhance the innovation management capacity of SMEs in Montenegro in order to improve their effectiveness and efficiency, in particular aimed at those with significant innovation activities and a real potential for international growth.

Keywords: monteenegro
Goal-directed eye-head coordination in dynamic multisensory environments (ORIENT)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: The Human Mind and Its Complexity
Panel description: Cognitive science, psychology, linguistics, theoretical philosophy
Countries involved: Netherlands,Portugal
Call: ERC Advanced Grant (ERC-2015-AdG, 2015)
Start date: 2017-01-01
End date: 2022-12-31
Duration (months): 72.0
Total project cost (EUR): 2523438.0
EU funding (EUR): 2209688.0
Participants: 2
Project status: CLOSED

Rapid object identification is crucial for survival of all organisms, but poses daunting challenges if many stimuli compete for attention, and multiple sensory and motor systems are involved in the processing, programming and generating of an eye-head gaze-orienting response to a selected goal. How do normal and sensory-impaired brains decide which signals to integrate (“goal”), or suppress (“distracter”)? Audiovisual (AV) integration only helps for spatially and temporally aligned stimuli. However, sensory inputs differ markedly in their reliability, reference frames, and processing delays, yielding considerable spatial-temporal uncertainty to the brain. Vision and audition utilize coordinates that misalign whenever eyes and head move. Meanwhile, their sensory acuities vary across space and time in essentially different ways. As a result, assessing AV alignment poses major computational problems, which so far have only been studied for the simplest stimulus-response conditions. My groundbreaking approaches will tackle these problems on different levels, by applying dynamic eye-head coordination paradigms in complex environments, while systematically manipulating visual-vestibular-auditory context and uncertainty. I parametrically vary AV goal/distracter statistics, stimulus motion, and active vs. passive-evoked body movements. We perform advanced psychophysics to healthy subjects, and to patients with well-defined sensory disorders. We probe sensorimotor strategies of normal and impaired systems, by quantifying their acquisition of priors about the (changing) environment, and use of feedback about active or passive-induced self-motion of eyes and head. I challenge current eye-head control models by incorporating top-down adaptive processes and eye-head motor feedback in realistic cortical-midbrain networks. Our modeling will be critically tested on an autonomously learning humanoid robot, equipped with binocular foveal vision and human-like audition.

Keywords: multisensory integration,spatial perception,dynamic feedback control
EU Patient- cEntric clinicAl tRial pLatform (EU-PEARL)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative 2
Action type: Research and Innovation actions
Partnership: IMI2 (Art-187)
Countries involved: Germany,Austria,Germany,Germany,Italy,Israel,Germany,Germany,Spain,Spain,Estonia,Belgium,Belgium,Switzerland,Belgium,Sweden,Belgium,Belgium,France,France,France,France,Netherlands,United States,Netherlands,United Kingdom,United Kingdom,United Kingdom,United Kingdom,Denmark,United Kingdom,United Kingdom,Luxembourg
Call: Integrated research platforms enabling patient-centric drug development (H2020-JTI-IMI2-2018-15-two-stage, 2018)
Start date: 2019-11-01
End date: 2023-04-30
Duration (months): 42.0
Total project cost (EUR): 25655310.32
EU funding (EUR): 12004952.5
Participants: 42
Project status: SIGNED

EU-PEARL has the ambition of transforming the current approach of conducting single-compound clinical trials into the use of cross-company Integrated Research Platforms (IRPs), taking into consideration both patients’ interests and the opportunities from novel molecules for addressing medical needs. Patient-centric data and knowledge sharing have the potential to accelerate the development of new treatments and reduce the operational costs of clinical trials. EU-PEARL will improve clinical effectiveness, patients’ satisfaction and societal access to timely and affordable medicines and it will shape the clinical trials of the future. This will change the industry paradigm from competition to cooperation in four disease areas and provide the framework for designing IRPs in other disease areas. The main objectives of EU-PEARL are: (1) To create a reusable, accessible and sustainable modular IRP for the design and execution of patient-centric, cross- company IRP in any disease area with unmet needs; (2) To set up the open, dynamic, patient inclusive IRP governance structure that will manage the appropriate regulatory, ethical, legal, statistical and data utilisation requirements of the IRP; (3) To disseminate and exploit the EU-PEARL paradigm through the provision of the necessary common tools, procedures, expertise and operational skills working to the highest scientific, regulatory and ethical standards and best practices, developed jointly by public and industry partners in a consensus-based approach; and (4) To create trial-ready IRP networks in the four disease areas of Major Depressive Disorder (MDD), Tuberculosis (TB), Non-Alcoholic Steatohepatitis (NASH) and Neurofibromatosis (NF).

Keywords: platform trial operations,bayesian statistics,data governance,sustainability,patient centredness,major depressive disorder,tuberculosis,non alcoholic steatohepatitis,neurofibromatosis
CBASS: Life, Death and cyclic nucleotides (CBASS)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Molecules of Life: Biological Mechanisms, Structures and Functions
Panel description: Molecular biology, biochemistry, structural biology, molecular biophysics, synthetic and chemical biology, drug design, innovative methods and modelling
Countries involved: United Kingdom
Call: ERC ADVANCED GRANT (ERC-2020-ADG, 2020)
Start date: 2021-08-01
End date: 2026-07-31
Duration (months): 60.0
Total project cost (EUR): 1785866.0
EU funding (EUR): 1785866.0
Participants: 1
Project status: SIGNED

All living things are subject to attack by viruses. Cells have evolved many different immune systems to protect themselves, including the adaptive and innate immune systems of vertebrates and the CRISPR and restriction:modification systems of bacteria. Viruses have developed potent countermeasures to subvert these systems, and this perpetual arms race has been a strong driving force in evolution throughout the history of life on Earth. CBASS (cyclic-oligonucleotide-based antiphage signalling systems) is a newly discovered bacterial immune system with evolutionary links to the eukaryotic cGAS-STING innate immune pathway. CBASS generates an astonishing array of cyclic di- and tri-nucleotide signalling molecules that in turn activate a diverse range of effector proteins to combat phage infection. These cyclic nucleotide second messengers thus lead to life or death decisions for infected cells. CBASS are abundant in pathogens and the microbes that dominate the human digestive system: this microbiome and the viruses that infect it are now implicated in diverse aspects of human health. This is a powerful and complex defence system, but fundamental aspects are not understood. How is viral infection detected by bacteria, triggering cyclic nucleotide production? What are the consequences for the cell: does activation inevitably lead to cell death, or is there a mechanism to switch it off? What role does protein modification play? Furthermore, how do viruses overcome CBASS defence? These questions will be addressed using a cutting-edge combination of structural and molecular biology, bioinformatics, biochemistry and microbiology. We propose a ground-breaking study of CBASS defence, with a focus on discovery of new enzymes, pathways and mechanisms. This work will open up new paradigms in bacterial cell signalling with broad implications for our understanding of microbial physiology, infection and the evolution of immune systems.

Keywords: cyclic nucleotide,crispr,abortive infection,bacteriophage